Comparative Pharmacology
Head-to-head clinical analysis: ARAMINE versus EPANED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARAMINE versus EPANED.
ARAMINE vs EPANED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Direct-acting sympathomimetic amine that stimulates alpha-adrenergic receptors, causing vasoconstriction and increased blood pressure.
Epaned contains enalapril maleate, an angiotensin-converting enzyme (ACE) inhibitor. Enalapril is a prodrug that is hydrolyzed to enalaprilat, which inhibits ACE, thereby reducing angiotensin II formation, decreasing vasoconstriction, aldosterone secretion, and sodium reabsorption.
Intravenous infusion: 1-10 mg initially, then 0.5-5 mg/hr titrated to blood pressure. Intramuscular or subcutaneous: 2-10 mg every 2 hours as needed.
0.2 mg/kg intravenously over 5 minutes every 2 hours; typical adult dose 10-20 mg IV.
None Documented
None Documented
Terminal elimination half-life is 2-4 hours. Clinical context: Requires continuous infusion for sustained blood pressure support.
Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 10-12 hours in moderate renal impairment (CrCl 30-50 mL/min) and 15-20 hours in severe impairment (CrCl <30 mL/min).
Primarily renal: 85% unchanged drug in urine within 24 hours. Biliary/fecal: <5%.
Renal excretion of unchanged drug accounts for approximately 30-40% of elimination; biliary/fecal excretion accounts for 50-60% as metabolites and unchanged drug.
Category C
Category C
Vasopressor
Vasopressor